Principal Investigator
Marijo Bilusic
Enrollment Status
Not Accepting
Clinical Trial ID
Institutional Protocol #
20231238
Clinical Trial Summary
A Randomized Open-Label Phase 2/3 Study of BT8009 as Monotherapy or in Combination in Participants with Locally Advanced or Metastatic Urothelial Cancer (Duravelo-2)
Phase
Phase II/III
Funding Agency/Sponsor
Industrial
Disease
Prostate, Bladder, and Kidney Cancers
Contact Information
Phone Number
305-243-2647